Hvis patienterne viser tegn på øvre luftvejsobstruktion (herunder øget tendens til at snorke) under behandling med somatropin, bør behandlingen afbrydes og en ny ENT- vurdering bør udføres.
If during treatment with somatropin patients show signs of upper airway obstruction (including onset of or increased snoring), treatment should be interrupted, and a new ENT assessment performed.